BPC-157 dosage: what the research record actually shows

Last updated 2026-07-23

Is there an official BPC-157 dosage for humans?

No. There is no approved dose for BPC-157 in humans because BPC-157 is not an FDA-approved drug. It does not appear in the Drugs@FDA database of approved drug products ^[1], and it is not on either the 503A bulk drug substances list for compounding pharmacies ^[2] or the 503B list for outsourcing facilities ^[3]. That absence matters more than most dosage charts admit: any specific milligram or IU number you see quoted online ("250 mcg twice daily," "500 mcg per injection") is coming from vendor convention, extrapolated animal math, or anecdote, not from a regulatory body or a clinical dosing study. The FDA's own bulk substances nomination list confirms BPC-157 has been formally proposed for the 503A list but has not been added, which means it sits in regulatory limbo, not approval ^[4]. A compounding pharmacy can only legally prepare a substance for a specific patient's prescription under 21 U.S.C. 353a when a licensed prescriber writes it and the pharmacy follows USP standards; that framework governs how it's dispensed, not what dose is medically proven to work ^[5]. So when people ask for "the" BPC-157 dosage, the honest answer is that no dose has cleared human trials at the size needed to set one. What follows is what the actual research record contains, and where the numbers you see in charts really come from.

Where do the numbers on BPC-157 dosage charts actually come from?

Almost all of them come from rodent studies, and they are reported as dose-per-body-weight (typically micrograms per kilogram, given by injection, oral gavage, or in drinking water), not as a flat human dose. A 2025 literature and patent review in Pharmaceuticals covering BPC-157's mechanisms and preclinical uses draws from exactly this kind of animal dosing data across many organ systems ^[6]. The tendon healing study by Krivic and colleagues, published in the Journal of Applied Physiology in 2011, is a good example of how these numbers get generated and later misapplied. Researchers gave BPC-157 to rats after transecting the Achilles tendon and found it promoted tendon outgrowth, cell survival, and cell migration in explant cultures ^[7]. That is a real, specific, useful finding for understanding mechanism. It is not a human dosing instruction. Rat metabolism, injection route, and body surface area to weight ratio are different enough from humans that a straight per-kg conversion is not considered valid pharmacology, and no paper in this record claims otherwise. This is worth saying plainly because most 'BPC-157 dosage for 200 lb male' charts circulating online are reverse-engineering a number from these animal studies and presenting it with false confidence. If a chart doesn't cite a specific human trial, assume it's a guess dressed up as a protocol.

What does the human research on BPC-157 dosing actually look like?

Small, early, and clinic-supervised. Two human studies stand out in the current record, and both used specific delivery methods, not oral capsules or generic subcutaneous shots. The first is a pilot study on intra-articular BPC-157 injections for knee pain, published in Alternative Therapies in Health and Medicine in 2021. Researchers injected BPC-157 directly into the knee joint of patients with various types of knee pain and reported improvement in pain and function ^[8]. This was a small pilot study, not a large randomized trial, and the injection was administered by a clinician directly into the joint space, a delivery method entirely different from a subcutaneous injection into the abdomen that most online protocols describe. The second is a 2024 pilot study on BPC-157 for interstitial cystitis symptoms, also in Alternative Therapies in Health and Medicine. It looked at whether BPC-157 improved bladder pain and urinary symptoms in a small group of patients ^[9]. Again: pilot-scale, symptom-focused, and administered under clinical supervision, not a self-dosing framework. Neither study gives you a body-weight dosing formula the way animal literature does, and neither has been replicated at scale. That is the entire human injection-dosing evidence base as of this writing. Everything else you'll find about BPC-157 dosage for humans is inference from rodent data, from injury-recovery forums, or from vendor product pages.

What does a typical BPC-157 dosage chart claim, and how should you read it?

Most charts you'll find online follow a similar pattern: a daily total split into one or two injections, scaled loosely by body weight, run for 2 to 6 weeks. Below is what that convention typically looks like, presented here for context on what's circulating, not as a validated protocol. | Body weight | Commonly cited daily total (vendor convention) | Typical split |

What does BPC-157 do for tendons and soft tissue, according to the research?

In animal and cell models, BPC-157 has been studied for its effects on tendon, ligament, muscle, and bone healing, largely through proposed effects on blood vessel formation and growth factor activity. A 2018 review in Current Pharmaceutical Design compared BPC-157's activity to standard angiogenic growth factors and summarized findings across gastrointestinal tract healing and musculoskeletal tissue healing in animal models ^[11]. A separate 2019 review in Cell and Tissue Research focused specifically on BPC-157's role in accelerating musculoskeletal soft tissue healing, again drawing on animal data ^[12]. A 2014 paper in Current Pharmaceutical Design examined BPC-157's relationship to blood vessels directly, a mechanism researchers propose underlies much of its tissue-healing activity in animal models ^[13]. This angiogenic mechanism is the throughline across most of the preclinical literature: the peptide is theorized to support new blood vessel growth into damaged tissue, which in turn is theorized to speed repair. Theorized and studied in animals is the accurate framing here; proven in humans is not. A 2025 systematic review in the HSS Journal specifically examined BPC-157's emerging use in orthopaedic sports medicine, pulling together the available literature (heavily preclinical, with the pilot human data noted above) to characterize where the evidence currently stands for tendon, ligament, and joint applications ^[14]. If you're researching BPC-157 specifically for tendon or ligament injury, that review is a more useful starting point than any dosage chart, because it tells you what's actually been tested and at what evidence tier.

How is BPC-157 dosage different for injectable versus oral use?

The human pilot studies used injection directly into a target site (the knee joint) or clinic-administered routes, not oral capsules ^[8][9]. Most retail 'BPC-157 dosage' content assumes subcutaneous injection into the abdomen, following an extrapolation from injectable animal-study routes, while oral capsule products are a separate, even less-studied delivery format with their own absorption questions that the current human literature does not resolve. A 2026 primer in the American Journal of Sports Medicine, aimed at orthopaedic and sports medicine physicians, walks through injectable peptide therapy broadly, including the practical and regulatory considerations physicians face when patients ask about compounds like BPC-157 ^[15]. That paper is written for clinicians deciding whether and how to discuss these therapies with patients, which tells you something: even the audience closest to actually administering these compounds is being handed a primer on uncertainty, not a dosing manual. If you're comparing injectable BPC-157 to oral forms, read BPC-157 peptide injections for how the delivery-method literature breaks down, since route of administration changes both theoretical bioavailability and the strength of any comparison to the animal-study route.

What is the BPC-157 and TB-500 blend, and does combining them change the dosage?

BPC-157 and TB-500 (a synthetic fragment related to thymosin beta-4) are frequently sold together as a 'combo' or 'blend' product, marketed for tissue repair. There is no human trial establishing a combined dosing protocol for these two peptides together. Each has its own separate, mostly-animal evidence base, and no citation in the current literature we've reviewed tests them as a combined regimen in humans. Vendor-suggested BPC-157/TB-500 blend dosing (commonly something like 250-300 mcg of each per injection, a few times weekly) is a commercial convention, not a study-derived figure. If a product page cites a dosage for the blend without linking to a specific trial testing that exact combination, that number did not come from research. It came from marketing convention layered on top of two separate single-peptide literatures, neither of which is settled in humans to begin with. Compare the two compounds directly at BPC-157 vs TB-500 before assuming a blend is simply 'more' of a good thing.

How do orthopedic and sports medicine physicians actually think about BPC-157 dosing right now?

Cautiously, and mostly in the context of managing patient expectations rather than writing prescriptions off a settled chart. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews looked at therapeutic peptides in orthopaedics broadly, covering applications, challenges, and where the field needs to go next, BPC-157 among the compounds discussed ^[16]. A 2025 paper in Arthroscopy asked directly whether injectable therapeutic peptides are a real adjunct to regenerative medicine and sports performance, or getting ahead of the evidence ^[17]. A 2026 review in Sports Medicine specifically addressed safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, a framing that matters because it separates peptides with an approval pathway from those, like BPC-157 currently, without one ^[18]. The consistent theme across this recent clinical literature (2025 and 2026 publications, not older enthusiasm-heavy pieces) is that physicians are being told to slow down, ask what tier of evidence supports a given peptide, and be explicit with patients about the preclinical-to-clinical gap rather than borrow confidence from animal data.

What are the risks of guessing at a BPC-157 dosage instead of using a provider-reviewed source?

The biggest risk isn't one specific side effect, it's dosing an unregulated product with no verified strength, sterility, or purity, based on a number nobody validated in humans. Because BPC-157 is not FDA-approved and not on the current 503A or 503B bulk lists ^[2][3], legitimate access runs through a prescriber and a licensed compounding pharmacy operating under 21 U.S.C. 353a ^[5], which at least gives you verified concentration and sterile compounding standards, even though the dose itself still hasn't been validated in a human trial. Self-sourced vials bought off a website with no prescription carry a different risk profile entirely: you don't know the actual concentration, you don't know the sterility of the compounding process, and the dosage chart you're following was likely built from rodent data or vendor convention rather than a human trial. Read BPC-157 peptide side effects for what the safety literature actually documents (again, mostly animal safety data with limited human pharmacovigilance) before assuming any dose, chart-derived or otherwise, is risk-free. BPC-157 Co works from research summaries like this one; when readers are ready to move past reading and actually consider use, the responsible next step is a provider review rather than a self-selected chart, with any dispensing handled through a licensed compounding pharmacy partner rather than an unregulated seller.

If there's no proven human dose, why do so many sources give exact numbers?

Because a specific number is more sellable and more shareable than an honest 'we don't know yet,' and because rodent studies do report exact numbers (micrograms per kilogram) that look precise even though they don't translate. A 2025 literature and patent review in Pharmaceuticals catalogs BPC-157's proposed mechanisms and possible medical applications across many preclinical findings, and reading it makes clear how much specific, quantified animal data exists alongside how little of it has been tested at equivalent scale in humans ^[6]. That gap, precise animal numbers plus almost no human dose-ranging data, is exactly what lets vendor pages and forum threads present confident-sounding charts. The charts aren't lying about having a number. They're implying the number came from proof that it works at that dose in people, and for BPC-157 today, that proof does not exist in the published record. If you want the fuller picture on what BPC-157 is and where the evidence stands, start with BPC-157 peptide, then use a BPC-157 dosage calculator only after a prescriber has reviewed your case, and check current BPC-157 for sale sourcing information so you understand what a legitimate, provider-reviewed supply chain looks like versus an unregulated one.

Frequently asked questions

What is the standard BPC-157 dosage per body weight?

There isn't a standard human dosage validated by trials. Body-weight-based dosing (micrograms per kg) appears in animal studies, not human protocols. Vendor charts that scale by body weight (for example, higher totals for a 200+ lb male) are extrapolating from that animal convention, not citing a human dose-ranging study, because none currently exists in the published record.

What is the BPC-157 dosage for a 200 lb male?

No published human trial specifies this. Commonly circulated vendor charts suggest roughly 300-400 mcg per day split into one or two injections for someone around 200 lb, but that figure comes from internet convention scaled off animal dosing math, not a clinical trial in men at that weight.

Is there an FDA-approved BPC-157 product or dose?

No. BPC-157 does not appear in the FDA's Drugs@FDA database of approved products, and it is not on the current 503A or 503B bulk drug substances lists used by compounding pharmacies, meaning there is no FDA-sanctioned dose for any indication.

How much BPC-157 did the human knee injection study use?

The 2021 pilot study in Alternative Therapies in Health and Medicine tested intra-articular BPC-157 injections directly into the knee joint for multiple types of knee pain and reported improvement, but it was a small pilot study, and the paper does not establish a standardized dose for general use outside that clinical setting.

Does BPC-157 dosage differ for oral versus injectable forms?

Yes, they're treated as different products with different, largely untested absorption profiles. The human pilot data involves direct clinical injection (intra-articular for knee pain, clinic-administered for interstitial cystitis), not oral capsules, so any oral dosing chart is extrapolating even further from the limited human evidence than injectable charts already do.

What is the BPC-157 and TB-500 blend dosage?

There is no human trial testing BPC-157 and TB-500 combined, so no blend dosage is study-derived. Commercial blend products (often around 250-300 mcg of each per injection) reflect vendor convention layered on top of two separate, mostly-animal single-peptide literatures, not a combined clinical protocol.

How long do people typically run a BPC-157 protocol, according to dosage charts?

Commonly cited ranges run 2 to 6 weeks in vendor and forum protocols. This duration convention is not derived from a human trial defining an optimal length; it mirrors informal injury-recovery timelines rather than a study that compared different treatment durations in people.

Is BPC-157 legal to buy and use at any dose?

BPC-157 sits outside FDA approval and outside the current 503A/503B compounding bulk lists, which puts its legal sourcing status in a gray zone. Legitimate access runs through a prescriber and licensed compounding pharmacy under 21 U.S.C. 353a; buying unregulated vials online for self-dosing carries separate legal and quality risks.

What did the BPC-157 interstitial cystitis pilot study use as a dose?

The 2024 pilot study in Alternative Therapies in Health and Medicine tested BPC-157 for interstitial cystitis symptoms in a small patient group under clinical supervision. It's an early pilot study, not a dose-ranging trial, so it doesn't establish a general-use dosage figure.

Can animal study doses be converted directly into a human BPC-157 dose?

No. Animal studies, including tendon-healing research using body-weight-based micrograms per kg, use rodent metabolism and physiology that don't convert linearly to humans. Every review in the current literature treats these as mechanistic findings, not as a basis for a human dosing formula.

Why do BPC-157 dosage charts vary so much between websites?

Because none of them are copying from an approved label or a human dose-ranging trial. Different vendors extrapolate differently from the same underlying animal data, which is why you'll see meaningfully different 'standard' doses for the same body weight across sites.

Should I use a BPC-157 dosage calculator instead of a fixed chart?

A calculator can help with arithmetic once you and a prescriber have settled on an approach, but it can't supply the missing piece: a human trial proving a specific dose works. Treat any calculator output as a math convenience, not clinical validation.

Sources

1. FDA, Drugs@FDA approved drug products database: BPC-157 does not appear in the FDA's database of approved drug products
2. eCFR, 21 CFR 216.23 (503A Bulks List): BPC-157 is not on the final 503A bulk drug substances list for compounding pharmacies
3. eCFR, 21 CFR 216.24 (503B Bulks List): BPC-157 is not on the 503B bulk drug substances list for outsourcing facilities
4. FDA, bulk drug substances nominated for use in compounding (current list): BPC-157 has been nominated for the 503A bulks list but has not been added
5. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Legal compounding requires a prescriber and licensed pharmacy operating under this statute
6. Pharmaceuticals (Basel), 2025, PMID 40005999: Literature and patent review cataloging BPC-157's proposed mechanisms and possible medical applications, based mainly on preclinical data
7. Journal of Applied Physiology, 2011, PMID 21030672: BPC-157 promoted tendon outgrowth, cell survival, and cell migration in a rat Achilles tendon and explant model
8. Alternative Therapies in Health and Medicine, 2021, PMID 34324435: Pilot study of intra-articular BPC-157 injections for multiple types of knee pain reported symptom improvement
9. Alternative Therapies in Health and Medicine, 2024, PMID 39325560: Pilot study examined BPC-157's effect on symptoms in patients with interstitial cystitis
10. Current Reviews in Musculoskeletal Medicine, 2025, PMID 40789979: Narrative review flags the gap between musculoskeletal healing claims for BPC-157 and the strength of controlled human evidence
11. Current Pharmaceutical Design, 2018, PMID 29998800: Review compares BPC-157 to standard angiogenic growth factors across GI tract and musculoskeletal tissue healing in animal models
12. Cell and Tissue Research, 2019, PMID 30915550: Review covers BPC-157's proposed role in accelerating musculoskeletal soft tissue healing in animal models
13. Current Pharmaceutical Design, 2014, PMID 23782145: Paper examines BPC-157's relationship to blood vessel formation as a proposed healing mechanism
14. HSS Journal, 2025, PMID 40756949: Systematic review characterizes the emerging, largely preclinical evidence for BPC-157 in orthopaedic sports medicine
15. American Journal of Sports Medicine, 2026, PMID 41476424: Primer for orthopaedic and sports medicine physicians on injectable peptide therapy considerations
16. JAAOS Global Research & Reviews, 2026, PMID 41490200: Review covers therapeutic peptides in orthopaedics, applications, challenges, and future directions
17. Arthroscopy, 2025, PMID 39265666: Paper questions whether injectable therapeutic peptides are a proven adjunct to regenerative medicine and sports performance
18. Sports Medicine, 2026, PMID 41966639: Review addresses safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injury and athletic performance